Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals stockholders approve increase in authorized common shares to 66 million

Neutral Impact 3 of 5 shareholder Written later

At its annual meeting on May 22, 2025, ANI Pharmaceuticals stockholders approved raising authorized common stock from 33,333,334 shares to 66,000,000 shares, effective on filing with the Delaware Secretary of State that day. They also elected eight directors and approved amended 2022 stock incentive and 2016 employee stock purchase plans. The filing does not say how the additional authorized shares will be used, but the increase gives the company room to issue more stock than before.

Key points

  • Authorized common shares increased from 33,333,334 to 66,000,000; the vote was 17,950,106 for and 461,824 against.
  • All eight director nominees were elected, with Renee P. Tannenbaum receiving the most against votes at 1,368,462.
  • Amended 2022 Stock Incentive Plan approved with 15,056,885 for and 1,202,893 against.
  • Advisory say-on-pay proposal approved with 14,565,587 for and 1,689,477 against.

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECMay 23, 2025, 7:00 AM ET
Accession number0001023024-25-000056

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 23, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.